Another genome-wide study, including sequence data of 91,002 participants, showed that carriers of NPC1L1 inactivating mutations, resulting in LDL-C reduction by ~12 mg/dL, were associated with a 53% relative CAD risk reduction [74]. The gene discussed is NPC1L1; the disease is coronary artery disorder.